Actinium Pharmaceuticals Inc (ATNM)

[dia76ca]

There are many near term catalysts...
1.Topline SIERRA data Q3 2022 (July?) already Orphan Drug Status in US and Europe
2.US and ROW Sierra partnership 2022
3. SIERRA BLA filing 1H 2023
4.Iomab-ACT CAR-T data 2022
5. GeneTx data 2022
6.Actimab-A + CLAG update 1H 2022
7.Actimab-A + Venetudax ph.2 1H 2022
8.AWE platform advances 2022
The very attractive European partnership should be followed by an US and ROW partnership. Or perhaps by a BO. Astellas is the 1000 lb. Gorilla in the room. If they like what they have seen so far they could buy up the whole company for a few $Billion. They have multi-Billions in cash! Chicken feed for them...but a nice return for Actinium investors!
No wonder H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) and set a price target of $45.00.